Asia Pacific Pancreatic Cancer Market - Segmented By Treatment Type, End Users & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Published: January, 2024
ID: 1206
Pages: 179

APAC Pancreatic Cancer Market Size (2022 to 2027)

The size of the pancreatic cancer market in the APAC region was worth USD 0.41 billion in 2022 and is estimated to be growing at a CAGR of 8.5 %, to reach USD 0.62 billion by 2027.

The studied market is mainly driven by the increasing prevalence of pancreatic cancer and the high demand for accurate diagnostic tests and treatment. Many local governments and non-profit organizations are taking awareness initiatives to fight against pancreatic cancer in the Asia-Pacific region. The demand for radiotherapy in Asia-Pacific is increasing to fight this cancer, as indicated in the report by Noorazrul Yahya et al., Published in the Asia-Pacific Journal of Clinical Oncology 2018. According to the estimates of this same report, it is expected to increase the number of radiotherapy fractions needed in 2025 and 2035 to 11.15 million and 14.17 million, respectively, from 7.63 million in 2018 in Southeast Asia.

Factors such as high unmet therapeutic demand in the general cancer market, growing concerns, and new developments in this treatment area contribute to the growth of the Pancreatic Cancer APAC market. Estimates show that only a tiny percentage (around 13% to 16%) of patients are diagnosed early enough to be treated with surgery, drugs, and chemotherapy. In addition, technological advances in diagnosis and treatment have led to more efficient and reliable solutions. These are the significant factors that have driven the growth of Pancreatic Cancer in the APAC market.

However, technologies for the rapid diagnosis of this type of cancer have not yet been fully developed due to this region's lack of health investments. Therefore, most patients with pancreatic cancer are diagnosed at an advanced stage of the disease. When diagnosed at an advanced stage of this type of cancer, treatment options are reduced due to the high rate of metastasis in the body, which leads to complications resulting in high death rates. These factors are limiting the growth of the pancreatic cancer therapeutics market in the APAC region. Another factor is poor results after treatment. This may be due to the low success rates of clinical trials of anticancer drugs, the unwanted side effects associated with anticancer drugs, or the high toxicity of these drugs in healthy cells.

Getting treatment for pancreatic cancer is expensive. Many people in developing and underdeveloped APAC regions find it difficult to pay for treatment. Most of the people in this region also have inadequate insurance policies. All these factors, as mentioned above, have a negative impact on the studied market.

This research report on the APAC pancreatic cancer market has been segmented & sub-segmented into the following categories:

By Treatment Type:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Others

By Cancer Type:

  • Exocrine Pancreas Cancer
  • Endocrine Pancreas Cancer

By End User:

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Asia-Pacific region is projected to see phenomenal growth during the forecast period due to improving technologies and drugs to treat pancreatic cancer. The two main countries in the Asia-Pacific region are India and China, with vast populations of around 1.48 billion and 1.39 billion people. Due to several factors, these markets will play a key role in increasing turnover. These factors include rapid urbanization, good health spending, significant investments by government authorities, improved health systems, and a growing senior population.

South Korea is expected to experience strong growth in the pancreatic cancer market. Much of this is due to excessive tobacco use and increased tobacco use, leading to a dramatic increase in the number of people diagnosed with pancreatic cancer. There is rapid growth in foreign investment and a growing interest in new processing strategies that will support this regional market.

Several multinational companies invest heavily in developing Asian economies to enter untapped markets. In addition, other APAC regional markets such as Australia, Taiwan, Singapore, and Japan are making unprecedented changes in medical practice, expanding their range of healthcare facilities, and increasing the adoption of targeted therapies to drive the APAC pancreatic cancer market during the forecast period.


Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., and NewLink Genetics Corp are a few of the notable players in the APAC pancreatic cancer market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample